| Objective/purpose: |
Collect
supportive and pivotal data needed to establish the effectiveness
of chloramine-T to control mortality caused by certain bacterial
diseases. |
| Drug name: |
Chloramine-T (Halamid®) |
Chloramine-T (Actamide) |
| Source of drug: |
Axcentive SARL/International Specialty Chemicals, Inc. |
B.L.
Mitchell, Inc. |
| Address: |
303 South Broadway
Suite 425
Tarrytown, NY 10591 |
1774 E
Azalea Dr.
Greenville, MS 38701-7505 |
| Contact: |
Larry Holzman
Telephone: 914-333-0606
Telefax: 914-333-0333
email: lbh@ischem.com |
Betty Mitchell
Phone: 662-686-9002
Fax: 662-686-9020
email: blmitchell@bellsouth.net |
| Target
pathogen(s): |
External
flavobacteriosis (e.g., bacteria responsible for bacterial gill disease and external
columnaris) |
| Method
of administration: |
Immersion:
flow-through or standing-bath treatment |
| Treatment
dosage: |
10, 15 or 20 mg/L for BGD and external columnaris in cold, cool and warmwater fish.
|
| Treatment
regimen: |
60 minutes per day for up to 3 days.
|
| Withdrawal
period: |
None.
Fish may be released or harvested for market immediately following
treatment. |
| Required
test parameters: |
Investigator
must collect mortality data throughout the 5-day pre-treatment,
treatment, and 14-day post-treatment periods. Investigator should
also report general fish behavior and any adverse effects relating
to treatment. |
| Limitations
or restrictions on use: |
Not for use on fish in culture systems with no outflows .
Investigator
must follow all instructions in the Study Protocol for INAD
9321 regarding drug acquisition and handling, fish treatment
and disposition, and data reporting requirements. |
| Required
INAD fee: |
$400.00
per facility per year |
| AADAP
contact for other information: |
Ms.
Bonnie Johnson, FWS - AADAP
Phone: 406-994-9905
Fax: 406-582-0242
bonnie_johnson@fws.gov |
| Disclaimer: |
Product and company names mentioned in this website, or mentioned in materials accessed via this website, are for informational purposes only. The mention of such does not imply endorsement by the Aquatic Animal Drug Approval Partnership, the U.S. Fish & Wildlife Service or any other organization of the U.S. Government. |
|
